DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

DAIC

MARCH 20, 2024

milla1cf Wed, 03/20/2024 - 18:50 March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve below-the-knee resorbable magnesium scaffold (BTK RMS). CLTI is associated with high rates of amputation and mortality as well as high care costs.1

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease 105

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S. JACC 2020.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stent Stents 105

DAIC

MAY 8, 2024

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 2024, [link]. 301–302, [link].

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111